Karuna Therapeutics, Inc. Common Stock
KRTX
KRTX was delisted on the 15th of March, 2024.
171 hedge funds and large institutions have $3.83B invested in Karuna Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 58 increasing their positions, 52 reducing their positions, and 15 closing their positions.
87% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 15
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
24% more call options, than puts
Call options by funds: $8.28M | Put options by funds: $6.7M
22% more capital invested
Capital invested by funds: $3.13B → $3.83B (+$693M)
12% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 52
8% more funds holding
Funds holding: 159 → 171 (+12)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$36.2M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$15.3M |
| 3 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$15.2M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$20.7M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$19.4M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$19.3M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
-$9.08M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$9.04M |
KRTX Hedge Fund Activity: Q4 2021 in Review
171 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Karuna Therapeutics, Inc. Common Stock (KRTX) for Q4 2021, worth a combined $3.83B — up 22% from $3.13B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new KRTX positions and 15 closed out — a net gain of 13 holders — while 58 added to existing stakes and 52 trimmed.
The largest buyer was Victory Capital Management, adding an estimated $36.2M. The largest seller was Logos Global Management, cutting an estimated $20.7M.
- 171 institutional investors held Karuna Therapeutics, Inc. Common Stock (KRTX) as of Q4 2021, up from 159 in Q3 2021.
- Funds reported $3.83B of Karuna Therapeutics, Inc. Common Stock stock for Q4 2021, up 22% quarter-over-quarter.
- 28 funds opened new Karuna Therapeutics, Inc. Common Stock positions in Q4 2021 and 15 closed out, a net change of +13 holders.
- The largest Karuna Therapeutics, Inc. Common Stock buyer in Q4 2021 was Victory Capital Management, an estimated $36.2M added.
- The largest Karuna Therapeutics, Inc. Common Stock seller in Q4 2021 was Logos Global Management, an estimated $20.7M sold.
Based on aggregated 13F filings for Q4 2021.